Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender
Elena Meseguer(Université Paris Cité), Pierre Amarenco(Hôpital Bichat-Claude-Bernard), Philippa C. Lavallée(Université Claude Bernard Lyon 1), Carlos Arnáiz(Inserm), Mikaël Mazighi(Inserm), Halim Abboud(Saint Joseph University), Tarik Slaoui(Inserm), Jean‐Marc Olivot(Stanford University), Bertrand Lapergue(Hôpital Foch), Guy Raphaeli(Inserm), Lucie Cabrejo(Délégation Paris 7), Céline Guidoux(Inserm), Isabelle Klein(Délégation Paris 7), Julien Labreuche(ASTER)
Cited by 54
Related Papers
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
|European Heart Journal|2011|1.2k
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
|The Lancet Neurology|2007|671